Pharmagupshup,pharmacy,free gpat material,niper,free niper material, pharma vacancy, pharma jobs, pharmacy seminar,pharma conference,pharma awards,pharma books,pharma study material,pharma services, pharma news,pharma colleges,pharma acts,sops

Wednesday, August 10, 2011

Closer to Transparency

To be sure, the road to clinical trials transparency is paved with good intentions—from the architects of, to the sponsors, to the "external" stakeholders. But this road is proving to be a difficult one to travel.

Nicholas Ide, chief architect of and contractor to the National Library of Medicine, offered some insights into these difficulties at a Center for Business Intelligence (CBI) conference last month in London. The Clinical Trials Registries and Results Databases conference—the first held outside the United States—covered global and U.S. requirements.

To date

Basic results reporting requirements went into effect September 27, 2008. As of last month, 250-plus results were submitted. Of those, approximately 46 had been "published" or made available on the site. So where are the balance of the results? Back to the sponsors for data clarification and cleanup.

"The data we have been getting is difficult to understand and the quality is pretty bad," Ide told the audience via teleconference. He provided actual examples of data errors, which are housed on the site.

However, one attendee responsible for transparency compliance at a large global pharma told Applied Clinical Trials that the company had submitted 40 results to the PRS database, and none have been approved.

Lisa Henderson
Applied Clinical Trials, Mar 1, 2009


Post a Comment

Copyright © Pharmagupshup | Powered by Pharmagupshup Hitesh Katariya